WO2011033361A3 - Combinación que comprendre un antimicrobiano como ácida fusídico, un glucocorticoide como betametasone y un antifúngico come clotrimazol - Google Patents

Combinación que comprendre un antimicrobiano como ácida fusídico, un glucocorticoide como betametasone y un antifúngico come clotrimazol Download PDF

Info

Publication number
WO2011033361A3
WO2011033361A3 PCT/IB2010/002301 IB2010002301W WO2011033361A3 WO 2011033361 A3 WO2011033361 A3 WO 2011033361A3 IB 2010002301 W IB2010002301 W IB 2010002301W WO 2011033361 A3 WO2011033361 A3 WO 2011033361A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
antimycotic
glucocorticoid
antimicrobial
combination
Prior art date
Application number
PCT/IB2010/002301
Other languages
English (en)
French (fr)
Other versions
WO2011033361A2 (es
Inventor
Raúl GARCÍA SALGADO LÓPEZ
Gustavo BARRANCO HERNÁNDEZ
Original Assignee
Laboratorios Senosiain S.A. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Senosiain S.A. De C.V. filed Critical Laboratorios Senosiain S.A. De C.V.
Priority to US13/496,164 priority Critical patent/US8895538B2/en
Priority to BR112012005895A priority patent/BR112012005895B8/pt
Priority to EP10816763.6A priority patent/EP2478908B1/en
Priority to CA2774356A priority patent/CA2774356C/en
Priority to ES10816763T priority patent/ES2716505T3/es
Publication of WO2011033361A2 publication Critical patent/WO2011033361A2/es
Publication of WO2011033361A3 publication Critical patent/WO2011033361A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Abstract

La presente invención se refiere a una composición farmacéutica tópica que comprende Ia combinación de un antimicrobiano, un glucocorticoide, un antimicótico y vehículos o excipientes farmacéuticamente aceptables; el proceso de fabricación de Ia composición y el uso de dicha composición para tratamiento de padecimientos localizados de dermatosis.
PCT/IB2010/002301 2009-09-15 2010-09-14 Combinación y composición que contiene un antimicrobiano, un glucocorticoide y un antimicótico WO2011033361A2 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/496,164 US8895538B2 (en) 2009-09-15 2010-09-14 Combination and composition that contains an antimicrobial, a glucocorticoid and an antimycotic
BR112012005895A BR112012005895B8 (pt) 2009-09-15 2010-09-14 combinação e composição contendo um agente antimicrobiano,um glucocorticóide e um agente antifúngico
EP10816763.6A EP2478908B1 (en) 2009-09-15 2010-09-14 Combination and composition that contains an antimicrobial, a glucocorticoid and an antimycotic
CA2774356A CA2774356C (en) 2009-09-15 2010-09-14 Combination and composition that contains an antimicrobial, a glucocorticoid and an antimycotic
ES10816763T ES2716505T3 (es) 2009-09-15 2010-09-14 Combinación y composición que contiene un antimicrobiano, un glucocorticoide y un antimicótico

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2009009884A MX2009009884A (es) 2009-09-15 2009-09-15 Combinacion y composicion que contiene un antimicrobiano, un glucocorticoide y un antimicotico.
MXMX/A/2009/009884 2009-09-15

Publications (2)

Publication Number Publication Date
WO2011033361A2 WO2011033361A2 (es) 2011-03-24
WO2011033361A3 true WO2011033361A3 (es) 2011-07-21

Family

ID=43759111

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/002301 WO2011033361A2 (es) 2009-09-15 2010-09-14 Combinación y composición que contiene un antimicrobiano, un glucocorticoide y un antimicótico

Country Status (15)

Country Link
US (1) US8895538B2 (es)
EP (1) EP2478908B1 (es)
AR (1) AR078370A1 (es)
BR (1) BR112012005895B8 (es)
CA (1) CA2774356C (es)
CO (1) CO6511242A2 (es)
CR (1) CR20120114A (es)
DO (1) DOP2012000065A (es)
EC (1) ECSP12011727A (es)
ES (1) ES2716505T3 (es)
GT (1) GT201200074A (es)
HN (1) HN2012000527A (es)
MX (1) MX2009009884A (es)
PE (1) PE20121351A1 (es)
WO (1) WO2011033361A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105687206A (zh) * 2014-11-27 2016-06-22 四川海思科制药有限公司 一种夫西地酸戊酸倍他米松乳膏药物组合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049468A1 (en) * 1980-10-06 1982-04-14 Schering Corporation Antifungal compositions comprising an antifungal agent and a corticosteroid
WO2010106465A1 (en) * 2009-03-17 2010-09-23 Sulur Subramaniam Vanangamudi A dermaceutical cream made using sodium fusidate, clotrimazole and fluticasone propionate
WO2010122475A1 (en) * 2009-04-20 2010-10-28 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, clotrimazole and mometasone, and a process to make it
WO2010122491A1 (en) * 2009-04-20 2010-10-28 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid, and an antifungal agent, and a process to make it

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656928B1 (en) * 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
RU2470645C2 (ru) * 2007-09-10 2012-12-27 Гленмарк Фармасьютикалс Лимитед Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049468A1 (en) * 1980-10-06 1982-04-14 Schering Corporation Antifungal compositions comprising an antifungal agent and a corticosteroid
WO2010106465A1 (en) * 2009-03-17 2010-09-23 Sulur Subramaniam Vanangamudi A dermaceutical cream made using sodium fusidate, clotrimazole and fluticasone propionate
WO2010122475A1 (en) * 2009-04-20 2010-10-28 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, clotrimazole and mometasone, and a process to make it
WO2010122491A1 (en) * 2009-04-20 2010-10-28 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid, and an antifungal agent, and a process to make it

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONIMO: "Fucicort-Creme", 14 October 2004 (2004-10-14), Retrieved from the Internet <URL:http://www.pharmazie.com/graphic/A/64/1-25564.pdf> *
DICCIONARIO OF ESPECIALIDADES FARMACEUTICAS., 2004, Retrieved from the Internet <URL:http://www.libreriamedica8a.com/productos/985.htm> *
FRACHI, G.: "Treatment of dermatological conditions with a combination of an antibacterial agent, an antifungal agent and an antiinflammatory steroid.", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY, THERAPY AND TOXICOLOGY., vol. 23, no. 9, 1985, pages 488 - 490, XP009167390 *
LARSEN, F.S. ET AL.: "An efficient new formulation offusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis.", ACTA DERM. VENEREOL., vol. 87, no. 1, 2007, pages 62 - 68, XP008162138 *

Also Published As

Publication number Publication date
AR078370A1 (es) 2011-11-02
WO2011033361A2 (es) 2011-03-24
HN2012000527A (es) 2014-09-22
GT201200074A (es) 2014-03-05
PE20121351A1 (es) 2012-10-27
EP2478908A4 (en) 2013-04-03
MX2009009884A (es) 2011-03-16
CR20120114A (es) 2012-06-08
CO6511242A2 (es) 2012-08-31
EP2478908B1 (en) 2018-12-26
ECSP12011727A (es) 2012-04-30
US20120178727A1 (en) 2012-07-12
US8895538B2 (en) 2014-11-25
BR112012005895B8 (pt) 2021-05-25
CA2774356C (en) 2017-05-30
ES2716505T3 (es) 2019-06-12
DOP2012000065A (es) 2012-05-31
BR112012005895B1 (pt) 2020-11-24
EP2478908A2 (en) 2012-07-25
CA2774356A1 (en) 2011-03-24
BR112012005895A2 (pt) 2017-06-06

Similar Documents

Publication Publication Date Title
WO2008156142A1 (ja) 新規なマロン酸スルホンアミド誘導体およびその医薬用途
WO2014107740A3 (en) Methods for reducing cellular proliferation and treating certain diseases
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
IL210813A0 (en) Methods of administering topical antifungal formulations for the treatment of fungal infections
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d&#39;au moins un de ses constituants
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2010032011A8 (en) Anti-fungal therapy
WO2011076212A3 (en) Processes for the manufacture of a pharmaceutically active agent
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2012140596A8 (en) Glycoside derivatives and uses thereof
GB201202095D0 (en) Topical medicament for the treatment of psoriasis
WO2011117870A3 (en) Compositions for topical administration
WO2011060253A3 (en) Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
WO2010027458A3 (en) Pdk inhibitor compounds and methods of use thereof
WO2007115286A3 (en) Combinations of therapeutic agents for treating cancer
WO2011033361A3 (es) Combinación que comprendre un antimicrobiano como ácida fusídico, un glucocorticoide como betametasone y un antifúngico come clotrimazol
MA32933B1 (fr) Combinaison d&#39;inhibiteurs de hspo90 et d&#39;herceptine
WO2011046905A3 (en) Pharmaceutical compositions
WO2010075314A3 (en) Topical formulations of flap inhibitors for the treatment of dermatological conditions

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: CR2012-000114

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 000327-2012

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 13496164

Country of ref document: US

Ref document number: 2774356

Country of ref document: CA

Ref document number: 12044629

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010816763

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10816763

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012005895

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012005895

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120315